Indications for a protective function of beta2-glycoprotein I in thrombotic thrombocytopenic purpura

British Journal of Haematology

Volumn 159, Issue 1, 2012, Pages 94-103

  Du, Vivian X ^a,b   van Os, Gwen ^a,c   Kremer Hovinga, Johanna A ^d   Dienava Verdoold, Ilze ^e   Wollersheim, Jacques ^b   Ruggeri, Zaverio M ^f   Fijnheer, Rob ^a   de Groot, Philip G ^a   de Laat, Bas ^a,b,f,g,h  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b SANQUIN RESEARCH   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UNIVERSITY OF BERN   (Switzerland)

^e Plasma Proteins Sequin Research   (Netherlands)

^f SCRIPPS RESEARCH INSTITUTE   (United States)

^g MAASTRICHT UNIVERSITY   (Netherlands)

^h Synapse BV   (Netherlands)

Author keywords

Beta2 glycoprotein I; Thrombotic thrombocytopenic purpura; Von Willebrand factor

Indexed keywords

BETA2 GLYCOPROTEIN 1; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE DISEASE; ARTICLE; BINDING SITE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIUM CELL; ERYTHROCYTE ADHESIVENESS; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REMISSION; THROMBOCYTE ADHESION; THROMBOCYTOPENIC PURPURA;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BETA 2-GLYCOPROTEIN I; BLOOD PLATELETS; CASE-CONTROL STUDIES; CELLS, CULTURED; ERYTHROCYTES; HEK293 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; PLATELET AGGREGATION; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RISTOCETIN; VON WILLEBRAND FACTOR;

EID: 84866315963     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12004     Document Type: Article

References (32)

1. Agar, C., de Groot, P.G., Levels, J.H., Marquart, J.A. & Meijers, J.C. (2009) Beta2-glycoprotein I is incorrectly named apolipoprotein H. Journal of Thrombosis and Haemostasis, 7, 235-236.
2. Agar, C., van Os, G.M., Mörgelin, M., Sprenger, R.R., Marquart, J.A., Urbanus, R.T., Derksen, R.H., Meijers, J.C. & de Groot, P.G. (2010) Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood, 116, 1336-1343.
3. 2-glycoprotein I: a novel component of innate immunity. Blood, 117, 6939-6947.
4. Arad, A., Proulle, V., Furie, R.A., Furie, B.C. & Furie, B. (2011) Beta-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood, 117, 3453-3459.
5. Arya, M., Anvari, B., Romo, G.M., Cruz, M.A., Dong, J.F., McIntire, L.V., Moake, J.L. & Lopez, J.A. (2002) Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood, 99, 3971-3977.
6. Beutler, E. & Gelbart, T. (1986) The mechanism of removal of leukocytes by cellulose columns. Blood Cells, 12, 57-64.
7. Dong, J.F., Moake, J.L., Nolasco, L., Bernardo, A., Arceneaux, W., Shrimpton, C.N., Schade, A.J., Mc Intire, L.V., Fujikawa, K. & Lopez, J.A. (2002) ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood, 100, 4033-4039.
8. Eckmann, C.M., De Laaf, R.T., Van Keulen, J.M., van Mourik, J.A. & de Laat, B. (2007) Bilirubin oxidase as a solution for the interference of hyperbilirubinemia with ADAMTS-13 activity measurement by FRETS-VWF73 assay. Journal of Thrombosis and Haemostasis, 5, 1330-1331.
9. Furlan, M., Robles, R., Galbusera, M., Remuzzi, G., Kyrle, P.A., Brenner, B., Krause, M., Scharrer, I., Aumann, V., Mittler, U., Solenthaler, M. & Lammle, B. (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. New England Journal of Medicine, 339, 1578-1584.
10. Groot, E., Fijnheer, R., Sebastian, S.A., de Groot, P.G. & Lenting, P.J. (2009) The active conformation of von Willebrand factor in patients with thrombotic thrombocytopenic purpura in remission. Journal of Thrombosis and Haemostasis, 7, 962-969.
11. Hammel, M., Kriechbaum, M., Gries, A., Kostner, G.M., Laggner, P. & Prassl, R. (2002) Solution structure of human and bovine beta(2)-glycoprotein I revealed by small-angle X-ray scattering. Journal of Molecular Biology, 321, 85-97.
12. Huizinga, E.G., Tsuji, S., Romijn, R.A., Schiphorst, M.E., de Groot, P.G., Sixma, J.J. & Gros, P. (2002) Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science, 297, 1176-1179.
13. Hulstein, J.J., de Groot, P.G., Silence, K., Veyradier, A., Fijnheer, R. & Lenting, P.J. (2005) A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Blood, 106, 3035-3042.
14. Hulstein, J.J., Lenting, P.J., de Laat, B., Derksen, R.H., Fijnheer, R. & de Groot, P.G. (2007) beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. Blood, 110, 1483-1491.
15. Ioannou, Y., Romay-Penabad, Z., Pericleous, C., Giles, I., Papalardo, E., Vargas, G., Shilagard, T., Latchman, D.S., Isenberg, D.A., Rahman, A. & Pierangeli, S. (2009) In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. Journal of Thrombosis and Haemostasis, 7, 833-842.
16. Jaffe, E.A., Nachman, R.L., Becker, C.G. & Minick, C.R. (1973) Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. Journal of Clinical Investigation, 52, 2745-2756.
17. Korporaal, S.J., Van Eck, M., Adelmeijer, J., Ijsseldijk, M., Out, R., Lisman, T., Lenting, P.J., van Berkel, T.J. & Akkerman, J.W. (2007) Platelet activation by oxidized low density lipoprotein is mediated by CD36 and scavenger receptor-A. Arteriosclerosis, Thrombosis and Vascular Biology, 27, 2476-2483.
18. de Laat, B., de Groot, P.G., Derksen, R.H., Urbanus, R.T., Mertens, K., Rosendaal, F.R. & Doggen, C.J. (2009) Association between beta2-glycoprotein I plasma levels and the risk of myocardial infarction in older men. Blood, 114, 3656-3661.
19. de Laat, B., van Berkel, M., Urbanus, R.T., Siregar, B., de Groot, P.G., Gebbink, M.F. & Maas, C. (2011) Immune responses against domain I of beta(2) -glycoprotein I are driven by conformational changes. Arthritis Rheumatism, 63, 3960-3968.
20. Lenting, P.J., Neels, J.G., van den Berg, B.M., Clijsters, P.P., Meyerman, D.W., Pannekoek, H., van Mourik, J.A., Mertens, K. & van Zonneveld, A.J. (1999) The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein. Journal of Biological Chemistry, 274, 23734-23739.
21. McNeil, H.P., Simpson, R.J., Chesterman, C.N. & Krilis, S.A. (1990) Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proceedings of the National Academy of Sciences of the United States of America, 87, 4120-4124.
22. Miyakis, S., Robertson, S.A. & Krilis, S.A. (2004) Beta-2 glycoprotein I and its role in antiphospholipid syndrome-lessons from knockout mice. Clinical Immunology, 112, 136-143.
23. Moake, J.L., Turner, N.A., Stathopoulos, N.A., Nolasco, L.H. & Hellums, J.D. (1986) Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. Journal of Clinical Investigation, 78, 1456-1461.
24. Oosting, J.D., Derksen, R.H., Hackeng, T.M., van Vliet, M., Preissner, K.T., Bouma, B.N. & de Groot, P.G. (1991) In vitro studies of antiphospholipid antibodies and its cofactor, beta 2-glycoprotein I, show negligible effects on endothelial cell mediated protein C activation. Thrombosis and Haemostasis, 66, 666-671.
25. Ruggeri, Z.M. & Zimmerman, T.S. (1981) The complex multimeric composition of factor VIII/von Willebrand factor. Blood, 57, 1140-1143.
26. Sadler, J.E., Moake, J.L., Miyata, T. & George, J.N. (2004) Recent advances in thrombotic thrombocytopenic purpura. Hematology/the Education Program of the American Society of Hematology, 1, 407-423.
27. Sodetz, J.M., Pizzo, S.V. & McKee, P.A. (1977) Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein. Journal of Biological Chemistry, 252, 5538-5546.
28. Stel, H.V., Sakariassen, K.S., Scholte, B.J., Veerman, E.C., van der Kwast, T.H., de Groot, P.G., Sixma, J.J. & van Mourik, J.A. (1984) Characterization of 25 monoclonal antibodies to factor VIII-von Willebrand factor: relationship between ristocetin-induced platelet aggregation and platelet adherence to subendothelium. Blood, 63, 1408-1415.
29. Takeuchi, R., Atsumi, T., Ieko, M., Takeya, H., Yasuda, S., Ichikawa, K., Tsutsumi, A., Suzuki, K. & Koike, T. (2000) Coagulation and fibrinolytic activities in 2 siblings with beta(2)-glycoprotein I deficiency. Blood, 96, 1594-1595.
30. Van den Biggelaar, M., Biering, R., Strom, G., Voorberg, J. & Mertens, K. (2007) Requirements for cellular co-trafficking of factor VIII and von Willebrand factor to Weibel-Palade bodies. Journal of Thrombosis and Haemostasis, 5, 2235-2242.
31. Verweij, C.L., Diergaarde, P.J., Hart, M. & Pannekoek, H. (1986) Full-length von Willebrand factor (vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit. The EMBO Journal, 5, 1839-1847.
32. Wijetilleka, S., Scoble, T. & Khamashta, M. (2012) Novel insights into pathogenesis, diagnosis and treatment of antiphospholipid syndrome. Current Opinion in Rheumatology, Prepublished online ahead of print; doi: 10.1097/BOR.0b013e328354ae8c.